Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL ANTHONY STEPHENS

Allopathic & Osteopathic Physicians Family Medicine

NPI
1801888607
CMS profile
81276
Location
ORANGE PARK, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,669.03

84 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,669.03 84

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL ANTHONY STEPHENS

NPI 1801888607 · CMS profile ID 81276

Allopathic & Osteopathic Physicians / Family Medicine

ORANGE PARK, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1801888607?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL ANTHONY STEPHENS, NPI 1801888607, CMS profile ID 81276. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801888607?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MICHAEL ANTHONY STEPHENS, NPI 1801888607, CMS profile ID 81276. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801888607?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MICHAEL ANTHONY STEPHENS, NPI 1801888607, CMS profile ID 81276, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1801888607?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

84 matching records · $1,669.03 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 84 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–84 of 84.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $13.6304/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204406785 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $19.2604/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241407149 CMS
Abbott Laboratories $17.1904/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240925985 CMS
Otsuka America Pharmaceutical, Inc. $19.4504/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227505144 CMS
AstraZeneca Pharmaceuticals LP $17.6404/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206701884 CMS
AstraZeneca Pharmaceuticals LP $14.8404/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206487440 CMS
Amgen Inc. $12.3304/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227216667 CMS
ABBVIE INC. $13.3304/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204406781 CMS
ABBVIE INC. $22.9404/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204406777 CMS
GlaxoSmithKline, LLC. $23.9404/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190373668 CMS
Otsuka America Pharmaceutical, Inc. $26.2004/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227505141 CMS
PFIZER INC. $21.6903/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231390278 CMS
Novo Nordisk Inc $21.6403/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188592503 CMS
AstraZeneca Pharmaceuticals LP $17.8103/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206275726 CMS
Abbott Laboratories $19.8503/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240909534 CMS
Novo Nordisk Inc $13.8402/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188786509 CMS
Novo Nordisk Inc $16.0402/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188242309 CMS
Bayer Healthcare Pharmaceuticals Inc. $23.7202/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225824959 CMS
Takeda Pharmaceuticals U.S.A., Inc. $27.0202/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223908109 CMS
ABBVIE INC. $9.6102/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204406773 CMS
ABBVIE INC. $17.7402/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204406769 CMS
Lundbeck LLC $26.1202/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251850721 CMS
Axsome Therapeutics, Inc. $26.2102/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235391817 CMS
Amgen Inc. $11.0902/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227216665 CMS
ABBVIE INC. $14.7701/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204406765 CMS
Exact Sciences Corporation $20.7801/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235363661 CMS
Antares Pharma, Inc. $16.4701/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235898227 CMS
Lundbeck LLC $34.4301/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251850719 CMS
ABBVIE INC. $15.7601/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204406761 CMS
Lilly USA, LLC $23.9201/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186752115 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $15.0701/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241407147 CMS
ABBVIE INC. $15.2201/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204406758 CMS
AstraZeneca Pharmaceuticals LP $140.5301/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206299556 CMS
Axsome Therapeutics, Inc. $28.1101/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235350159 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,342.37 82
PY2020 $1,350.25 82
PY2021 $1,899.92 123
PY2022 $1,815.09 103
PY2023 $1,665.56 97
PY2024 $1,677.74 90
PY2025 $1,669.03 84

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $514,075.73 130
PY2024 Principal investigator $896,445.94 51
PY2023 Principal investigator $862,083.85 58
PY2022 Principal investigator $615,501.62 51
PY2021 Principal investigator $419,357.81 67
PY2020 Principal investigator $818,617.33 37
PY2019 Principal investigator $29,331.51 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

130 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271052
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271054
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271056
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271058
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271060
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271062
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271064
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271066
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271068
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271070
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271072
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271074
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271076
Principal investigator 1 Seqirus USA Inc $400.40 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271092
Principal investigator 1 Seqirus USA Inc $400.40 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271095
Principal investigator 1 Seqirus USA Inc $400.40 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271104
Principal investigator 1 Seqirus USA Inc $788.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271108
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271110
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271114
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271118
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271120
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271124
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271126
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271128
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271130
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271132
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271134
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271136
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271138
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271140
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271142
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271144
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271146
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271148
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271150
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271152
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271154
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271156
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271158
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271160
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271162
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271164
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271166
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271168
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271170
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271172
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271174
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271176
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271178
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271180
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271182
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271184
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271186
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271188
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271190
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271192
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271194
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271196
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271198
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271200
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271202
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271204
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271206
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271208
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271210
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271212
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271214
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271216
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271218
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271220
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271222
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271224
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271226
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271228
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271232
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271234
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271236
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271238
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271240
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271242
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271244
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271246
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271248
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271252
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271254
Principal investigator 1 Seqirus USA Inc $1,500.00 11/17/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271112
Principal investigator 1 Seqirus USA Inc $4,274.00 11/03/2025 Non-covered Recipient Entity
Fleming Island Center for Clinical Research
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810854
Principal investigator 1 Seqirus USA Inc $1,174.50 11/03/2025 Non-covered Recipient Entity
Fleming Island Center for Clinical Research
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810858
Principal investigator 1 Seqirus USA Inc $11,000.00 10/03/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271116
Principal investigator 1 Seqirus USA Inc $2,000.00 10/03/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271318
Principal investigator 1 Seqirus USA Inc $4,925.00 10/03/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271322
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,253.30 09/24/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067677
Principal investigator 1 Seqirus USA Inc $110.98 09/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271306
Principal investigator 1 Seqirus USA Inc $111.30 09/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271308
Principal investigator 1 Seqirus USA Inc $946.80 09/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271316
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $6,250.00 09/05/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067675
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,000.00 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEA
Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185553463
Principal investigator 1 ModernaTX, Inc. $337.50 08/06/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985344
Principal investigator 1 ModernaTX, Inc. $9,376.30 08/06/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985354
Principal investigator 1 ModernaTX, Inc. $67.50 08/06/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985358
Principal investigator 1 ModernaTX, Inc. $3,078.00 08/06/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985360
Principal investigator 1 ModernaTX, Inc. $12,663.60 08/06/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985362
Principal investigator 1 ModernaTX, Inc. $6,519.15 08/06/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985370
Principal investigator 1 ModernaTX, Inc. $4,876.95 08/06/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985372
Principal investigator 1 ModernaTX, Inc. $134,206.35 08/06/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985376
Principal investigator 1 ModernaTX, Inc. $216.00 08/06/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985378
Principal investigator 1 ModernaTX, Inc. $1,094.85 08/06/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985382
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $132.00 07/02/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066991
Principal investigator 1 ModernaTX, Inc. $1,200.00 04/11/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985380
Principal investigator 1 ModernaTX, Inc. $675.00 04/04/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985350
Principal investigator 1 ModernaTX, Inc. $1,162.35 04/02/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985352
Principal investigator 1 ModernaTX, Inc. $361.80 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985356
Principal investigator 1 ModernaTX, Inc. $67.50 03/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985346
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $400.00 03/12/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067265
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $132.00 03/05/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067261
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $264.00 03/05/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067263
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,862.00 02/28/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067767
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $264.00 02/26/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067765
Principal investigator 1 ModernaTX, Inc. $1,350.00 02/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985364
Principal investigator 1 ModernaTX, Inc. $500.00 02/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985366
Principal investigator 1 ModernaTX, Inc. $1,500.00 02/19/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985348
Principal investigator 1 ModernaTX, Inc. $67.50 02/19/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985374
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $9,175.00 01/28/2025 Non-covered Recipient Entity
FLEMING ISLAND CENTER FOR CLINICAL RESEARCH
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Lumbosacral Radiculopathy No dispute reported 06/30/2026 1214123726
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $4,237.95 01/22/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067831
Principal investigator 1 ModernaTX, Inc. $500.00 01/22/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252985368
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $264.00 01/17/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067829
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $650.00 01/14/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067827
Principal investigator 1 AstraZeneca UK Limited $12,073.60 01/13/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEA
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185553465
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $3,683.15 01/13/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067825
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,700.00 01/03/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEA
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185553467